Howell Biopharma was inspired by the need to provide health and wellness options to serve the needs of all people. Howell is a Canadian company established to address the goals of the federal and provincial governments to provide universal health care at a cost the governments can afford. Howell markets, distributes, and produces selected pharmaceutical products primarily for the wholesale hospital, pharmacy, and senior living sectors (including independent living, assisted living, long-term care, memory care facilities, etc.) based on Howell’s access to those sectors and its understanding of the Canadian provincial healthcare system, as well as other markets.
Many of Howell’s product offerings will be topical or will utilize dermal-delivery technologies, including but not limited to pain relief and pain management. These include specialty formulations for dermatology, cosmetology, and inflammatory disease treatment. In addition to distributing these traditional pharmaceutical products, in both OTC and Rx formulations, the Company also plans to develop and distribute Cannabidiol-based (“CBD”) products for prescribed use in pain management and anti-opioid applications.
Howell intends to expand distribution and production of its pharmaceutical products under license into Canada primarily through institutional and B2B and B2C channels. The Company will subsequently distribute to other markets (including but not limited to selected U.S. states, Europe, South Africa, Australia, India, China, and Ukraine). The Company is also entering the retail sector through contractual arrangements, as well as direct, online distribution.
Howell holds or will hold, directly and through its affiliates, exclusive manufacturing rights and licenses, patents and intellectual property. It plans to expand those products with its own R&D capabilities and joint-venture arrangements with select academic institutions.
Products